Cardiovascular disease (CVD) is the leading cause of death for both men and women in the United States. CVD is a general term for diseases affecting the heart and blood vessels. Adults with diabetes are nearly twice as likely to die from heart disease or stroke as people without diabetes. But did you know that women with diabetes are twice as likely to have a second heart attack, and four times more likely to have heart failure than women without diabetes? Furthermore, according to the American College of Obstetricians and Gynecologists, women have unique risk factors for CVD that men do not share.
Ninety percent of women have one or more risk factors for heart disease or stroke and studies have suggested that women’s reproductive factors are associated with their risk of cardiovascular disease. Reproductive factors provide an early window into a woman’s heart disease risk and studies suggest knowing these risks, before the onset of established heart disease risk factors, could be used to predict which women are most likely to experience a future heart disease event.
LifeStory Health, a biotech company in Boston, MA, has identified a novel biological mechanism based on modified proteins found in the menstrual blood that arises from a unique hormonal cascade, offering a window into early-stage disease and treatment. An earlier “window” of detection into a woman’s level of CVD risk could allow for earlier prevention. Until now, the contribution of reproductive factors to heart disease risk characterization has been vague. LifeStory Health’s new development could bring certainty by using the Company’s patent-pending technology that stratifies women using menstrual blood. This technology may provide that early window by assessing whether a woman’s risk of CVD is low, medium, or high based on her own biology using menstrual blood.
Data suggests that reproductive information may be the most useful in premenopausal women, and possibly prior to the development of traditional risk factors such as hypertension, diabetes, dyslipidemia. Among younger women, reproductive factors often precede the onset of established CVD risk factors and could thus guide risk factor modification. When examined in conjunction with traditional risk factors, such as diabetes, the findings may be even more of an indicator of suffering a heart disease event.
CVD risk factors that are unique to women
CVD risk factors that are unique to women include:
- Polycystic ovary syndrome (PCOS): PCOS is a leading cause of infertility that can affect all areas of the body, not just the reproductive system. Having PCOS increases the risk of diabetes and may increase the risk of CVD. No one knows the exact cause of PCOS but it occurs when a woman’s ability to process glucose is impaired. Since PCOS causes high glucose levels, it can be helpful for pregnant women with PCOS to have earlier screenings for gestational diabetes during pregnancy.
- Gestational diabetes: Diabetes that first appears during pregnancy increases the risk of developing diabetes and CVD after pregnancy. Women who have had gestational diabetes should be tested for diabetes 6–12 weeks after childbirth and then every 3 years.
- Gestational hypertension: Having high blood pressure during pregnancy increases the risk of having CVD and high blood pressure later in life. The risk of serious blood pressure-related complications with a future pregnancy is also increased.
- Preeclampsia: This disorder can occur during pregnancy or after childbirth. If it is not diagnosed and treated, it can lead to serious health problems. Women who have had preeclampsia are at a greater risk of developing CVD. Pre-eclampsia tends to be more common in women with diabetes.
The correlation between reproductive disorders and diabetes makes this more than just an issue impacting older adult. The preliminary findings of a study from Denmark suggest that children and young adults with diabetes may have seven times the risk of sudden cardiac death than young people without the disease. Serious cardiovascular disease can begin before the age of 30 in people with diabetes. According to the American Diabetes Association (ADA), damage to the coronary arteries is two to four times more likely in asymptomatic people with type 1 diabetes than in the general population. Because symptoms may be absent at first, the ADA recommends early diagnosis, treatment, and management of cardiac risk factors.
The burden of diabetes is hard on women
“The burden of diabetes can be especially hard on women. Unique to women, it can lead to increased risk factors during pregnancy to both the mother and child, it can create sexual health issues and add additional risk factors when using birth control. In the future, we need to better understand the relationship between diabetes and women.”
LifeStory Health’s patient stratification technology, either alone or in concert with established factors, may enhance the ability to stratify women in a simple and cost-effective way. Every 80 seconds a woman dies from heart disease and it is not just reserved for post-menopausal women. Premenopausal women may have an opportunity to prevent being one of the 44 million deaths from CVD and we might have menstrual blood to thank.
Women’s Heart Health Related Article:
What World Heart Day Means to Me (and You)
The Impact of Traumatic Events on Women’s Heart Health
Related Content: What You Need To Know About Recurrent Pregnancy Loss
Anna Villarreal is the SVP of Business Development for The Doctor Weighs In. She is also the Editor of the Women's Health section. In that role, she recruits physicians and other credible authors to contribute original content on topics of interest to our female readers. In addition, she is a regular contributor to the site.
Anna is the Founder and CEO of LifeStory Health, a lab testing company specifically for women of menstruating age. LifeStory Health (LSH) delivers personal health services as well as supports healthcare and research organizations. Results are securely sent using LSH's HIPAA-compliant texting service giving women deeper insights into their health with the touch of a button.
Prior to commercializing LifeStory Health, Inc., LSH’s novel scientific discovery has received several notable awards, including the First Place Award at Harvard University’s 19th Annual Northeast Chemistry Research Conference and The American Chemical Society & Regional Affiliates for the best Elevator Pitch Award (sponsored by JEOL USA, Inc.), Best Overall Innovation and First Place in the ConnectIN category from Northeastern University’s Research, Innovation, and Scholarship Expo (RISE) for the discovery of novel and revolutionary inventions or processes that can be translated into real-world applications, and the Best Graduate Student Poster from the 2017 International Society of Pharmaceutical Engineering (ISPE) Boston Chapter, with subsequent representation at the international poster competition.
A strong advocate for women's healthcare, Anna's pioneering vision to map the menstrual blood proteome through a set of resolute, data-leading principles and an award-winning scientific methodology has led to extraordinary discoveries. Anna's discoveries and steadfast approach to putting the patient first is featured in over 40 publications world-wide. LifeStory Health has completed two clinical trials including Screening of Cancer Through Novel Female Specific Biomarkers in partnership with the largest non-profit healthcare system in Texas and one of the largest in the country.
To promote Innovation, Anna serves as a guest-lecturer and project sponsor at Northeastern University for several graduate-level programs. These Master-level courses include Data Analytics, Statistical Analysis, Chemistry, Regulatory Affairs, and Business Administration. Anna also serves as a project sponsor for the top 40 highest-performing students at the undergraduate level.
Anna’s style is to shine a bright light on the need for change and innovation in all the organizations that she has been involved in. This has been a consistent theme throughout her life. For example, Anna was an original influencer in the National Women’s Soccer League, the first professional women’s soccer league to survive long-term.
Anna is the Director of Philanthropy for the New England Football Club (NEFC), one of the USA’s largest youth soccer organizations. NEFC’s philanthropic initiatives have benefited thousands of children and Anna has raised nearly 100% of the operating budget that supports these initiatives as well as established long-term corporate partnerships. Anna is also on the planning committee for Children's Vision Advocacy Day at the State House, which led the successful Massachusetts legislation change requiring mandates in children’s vision care.
Anna spends most of her time at her Boston home while spending the winters down in sunny Florida.